Stock CTXR CITIUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.6648 USD -9.25% Intraday chart for Citius Pharmaceuticals, Inc. -11.88% -12.12%
Apr. 26 Citius Pharmaceuticals Launches $15 Million Offering MT
Apr. 11 Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma CI

Business Summary

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

Number of employees: 22

Managers

Managers TitleAgeSince
Leonard Mazur CEO
 Chief Executive Officer 79 13-06-30
Jaime Bartushak DFI
 Director of Finance/CFO 57 17-11-26
Preeti Singh CTO
 Chief Tech/Sci/R&D Officer - 21-12-31
Myron Czuczman CTO
 Chief Tech/Sci/R&D Officer 65 20-07-13
Alan Lader CTO
 Chief Tech/Sci/R&D Officer - 16-02-29
Gary Talarico COO
 Chief Operating Officer 69 16-02-29
Myron Holubiak BRD
 Director/Board Member 77 15-09-30
Ilanit Allen IRC
 Investor Relations Contact - 21-05-16
Catherine Kessler LAW
 General Counsel - 22-02-09
Paul Sowyrda PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Myron Holubiak BRD
 Director/Board Member 77 15-09-30
Dennis McGrath BRD
 Director/Board Member 67 23-02-06
Leonard Mazur CEO
 Chief Executive Officer 79 13-06-30
Carol Webb BRD
 Director/Board Member 78 16-02-29
Suren Dutia BRD
 Director/Board Member 82 15-09-30
Eugene Holuka BRD
 Director/Board Member 65 16-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 159,094,781 146,786,842 ( 92.26 %) 0 92.26 %

Shareholders

NameEquities%Valuation
Leonard Mazur
6.446 %
10,255,343 6.446 % 9 M $
BlackRock Advisors LLC
5.106 %
8,124,019 5.106 % 7 M $
Vanguard Fiduciary Trust Co.
4.337 %
6,900,230 4.337 % 6 M $
Geode Capital Management LLC
1.747 %
2,779,908 1.747 % 2 M $
STATE STREET CORPORATION
1.387 %
2,207,361 1.387 % 2 M $
Myron Holubiak
1.252 %
1,992,243 1.252 % 2 M $
Osaic Wealth, Inc.
0.6059 %
963,956 0.6059 % 864 669 $
Northern Trust Investments, Inc.(Investment Management)
0.6046 %
961,965 0.6046 % 862 883 $
Teachers Advisors LLC
0.3046 %
484,649 0.3046 % 434 730 $
Charles Schwab Investment Management, Inc.
0.2244 %
356,994 0.2244 % 320 224 $

Company contact information

Citius Pharmaceuticals, Inc.

11 Commerce Drive 1st floor

07016, Cranford

+908 967 6677

http://www.citiuspharma.com
address Citius Pharmaceuticals, Inc.(CTXR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6648 USD
Average target price
4 USD
Spread / Average Target
+501.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CITIUS PHARMACEUTICALS, INC. Stock Citius Pharmaceuticals, Inc.
-12.12% 120M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.20% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CTXR Stock
  4. Company Citius Pharmaceuticals, Inc.